Replimune Group (NASDAQ:REPL) Stock Rating Lowered by ValuEngine

ValuEngine lowered shares of Replimune Group (NASDAQ:REPL) from a buy rating to a hold rating in a research report report published on Friday morning, ValuEngine reports.

A number of other research firms have also recently issued reports on REPL. Zacks Investment Research cut Replimune Group from a buy rating to a hold rating in a report on Tuesday, August 20th. JPMorgan Chase & Co. upgraded Replimune Group from a neutral rating to an overweight rating and dropped their price objective for the company from $27.00 to $26.00 in a report on Friday, July 12th. Chardan Capital restated a buy rating and set a $28.00 price objective on shares of Replimune Group in a report on Thursday, August 15th. Roth Capital began coverage on Replimune Group in a report on Wednesday, September 4th. They set a buy rating and a $20.00 price objective for the company. Finally, HC Wainwright began coverage on Replimune Group in a report on Monday, July 8th. They set a buy rating and a $26.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Replimune Group presently has an average rating of Buy and a consensus target price of $23.33.

NASDAQ REPL opened at $15.75 on Friday. The company has a market cap of $457.58 million, a P/E ratio of -11.84 and a beta of 3.12. The business’s 50 day moving average price is $11.46 and its 200-day moving average price is $13.35. Replimune Group has a fifty-two week low of $8.88 and a fifty-two week high of $19.90.

Replimune Group (NASDAQ:REPL) last released its earnings results on Wednesday, August 14th. The company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.02. On average, research analysts expect that Replimune Group will post -1.52 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the business. BNP Paribas Arbitrage SA purchased a new stake in shares of Replimune Group in the 1st quarter worth $38,000. Rhumbline Advisers purchased a new stake in shares of Replimune Group in the 1st quarter worth $174,000. Morgan Stanley lifted its holdings in shares of Replimune Group by 793.0% in the 2nd quarter. Morgan Stanley now owns 20,709 shares of the company’s stock worth $304,000 after buying an additional 18,390 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Replimune Group by 211.3% in the 2nd quarter. Wells Fargo & Company MN now owns 23,090 shares of the company’s stock worth $338,000 after buying an additional 15,672 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Replimune Group by 1.2% in the 2nd quarter. Northern Trust Corp now owns 123,931 shares of the company’s stock worth $1,817,000 after buying an additional 1,437 shares during the period. Institutional investors and hedge funds own 60.74% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Featured Story: How the Consumer Price Index (CPI) is calculated?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.